Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
CEPHALON International biopharmaceutical research company | WORLDWIDE SITES | KEY DATES 1987 Creation by Frank Baldino Jr., Ph.D. 1991 NASDAQ IPO (CEPH) 1994 MODIODAL® (modafinil) launch in France, first in a new class of wakefulness promoting agents for treating disabling excessive daytime sleepiness disorders 1998 PROVIGIL® ( modafinil) launch in the UK/Ireland 1999 PROVIGIL® launch in the US 2000 Acquisition of ACTIQ® (fentany citrate) for the treatment of BreakThrough cancer Pain (BTcP) 2001 Acquisition of Louis Lafon Laboratories in France 2004 Acquisition of CIMA Labs, Inc., a leader in drug delivery technologies 2005 Acquisitions: | KEY FIGURES 3000 people worldwide of which 300 in R&D and 900 in Europe Over 30 drugs marketed in more than 50 countries Revenues: $1.97 billion in 2008 R&D investments: 18 % of 2008 revenues Cephalon is listed on the NASDAQ (CEPH), since 1991, and was recently added to the NASDAQ-100 Index, which includes 100 of the largest high-tech securities. ▬ TREANDA® (bendamustine) for haematological malignancies in the United States only ▬ TRISENOX® (arsenic trioxide) for Acute Promyelocytic Leukaemia (APL) ▬ Zeneus Pharma Ltd, a European company specialised in oncology 2006 ▬ Creation of a Joint Venture in Asia ▬ Launch of MODIODAL® (modafinil) in Japan 2007 Acquisition of AMRIX® (cyclobenzaprine hydrochloride extended-release capsules) a myorelaxant for relief of muscle spasm, in the United States only 2008 TREANDA® (bendamustine hydrochloride) launch For the second time, Cephalon was highlighted on the Fortune 1000 annual ranking of America’s largest corporations. Cephalon is one of only 19 companies in the pharmaceutical sector to make FORTUNE magazine’s list. The World Economic Forum in Davos inducted Cephalon into its “Community of Global Growth Companies” in 2006 and thus highlighted Cephalon as one of the next generation of global multinational companies. Added in 2008 to the Standard & Poor’s 500 Index considered as the best single gauge of the US equities market in the US in: - Chronic Lymphocytic Leukaemia (CLL) - Relapsed Indolent Non-Hodgkin’s Lymphoma (NHL) 2009 ▬ EFFENTORA® pan European launch in BreakThrough cancer Pain ▬ Acquisitions: - Ception Therapeutics, Inc., whose lead product, reslizumab, is a humanised monoclonal antibody against interleukin-5 - Lupuzor™, for the treatment of systemic lupus erythematosus - Arana Therapeutics, an Australian biopharmaceutical company on next generation antibodies in inflammatory diseases and cancer ▬ NUVIGIL® (armodafinil) launch in the US | EUROPEAN SITES AND MORE Over the past 8 years, Cephalon has invested close to $1 billion to strengthen its European infrastructure In addition to its direct presence in 19 European countries, Cephalon has partnerships in nearly 50 countries within Europe, the Middle East and Africa | Key Medications in Europe, Middle-East and Africa Central Nervous System Pain PROVIGIL®/MODIODAL®/VIGIL®/MODASOMIL® (modafinil): a wake promoting agent for disabling excessive daytime sleepiness disorders related to narcolepsy, OSA/HS (Obstructive Sleep Apnoea/Hypopnea Syndrome) and SWSD (Shift Work Sleep Disorders) GABITRIL® (tiagabine): an antiepileptic drug used in adjunct therapy for treatment of partial seizures OTRASEL®/ZELAPAR®/XILOPAR® (selegiline freeze-dried tablets): for Parkinson’s disease Breakthrough Cancer Pain (BTCP) in adult patients who are already receiving maintenance opioid therapy for their persistent pain - ACTIQ® (oral transmucosal fentanyl citrate): using a transmucosal delivery system on a plastic handle - EFFENTORA® (fentanyl buccal tablet): a new formulation using OraVescent® technology which enhances the rate and extent of fentanyl absorption through the buccal mucosa Oncology, Haematology & associated infections Primary Care MYOCET® (liposomal doxorubicin): indicated in combination with cyclophosphamide for first-line treatment of metastatic breast cancer TRISENOX® (arsenic trioxide): for the treatment of relapsed or refractory Acute Promyelocytic Leukaemia (APL) a specific form of Acute Myeloid Leukeamia (AML) TARGRETIN® (bexarotene): a treatment for cutaneous T-cell lymphoma ABELCET® (amphotericin B lipid complex): for the treatment of invasive fungal infections in patients who are refractory or intolerant of a conventional amphotericin B therapy, mostly prescribed to patients suffering from cancer SPASFON®/SPASFON-LYOC®(phloroglucinol/trimethylphloroglucinol): an antispasmodic indicated in abdominal pain for various diseases NAXY®/MONONAXY® (clarythromycin): a broad spectrum antibiotic PARALYOC® (paracetamol): an analgesic-antipyretic for relief of mild to moderate pain and febrile states PROXALYOC® (piroxicam): a non steroidal anti-inflammatory medication treating arthroses and arthritis LOPERAMIDE-LYOC® (loperamide): for acute and chronic diarrheas Products listed above are not necessarily marketed in all European, Middle East and African countries nor in all indications Updated-January 2010 Contact: Marie-Dominique de La Salle/ Communications & Public Affairs Tel. +33 1 49 81 82 48 – [email protected]